Using targeted PET imaging to diagnose Multiple System Atrophy
Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy
Central South University · NCT06890377
This study is testing a new type of imaging to see if it can help doctors better diagnose and understand the different forms of Multiple System Atrophy in people over 35 who have already been diagnosed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 35 Years to 80 Years |
| Sex | All |
| Sponsor | Central South University (other) |
| Locations | 1 site (Hunan, Changsha) |
| Trial ID | NCT06890377 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize targeted α-synuclein PET imaging to explore the pathological load and spatial distribution of α-synuclein in patients diagnosed with Multiple System Atrophy (MSA). The study will assess the effectiveness of this imaging technique as a biomarker for diagnosing different subtypes of MSA, evaluating disease severity and prognosis. Participants will include individuals over 35 years old with clinically confirmed or probable MSA, who have been ruled out for other genetic conditions. The study will not involve any specific interventions or treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals over 35 years old with clinically confirmed or probable Multiple System Atrophy.
Not a fit: Patients with other neurological disorders or those who cannot undergo neuroimaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of diagnosing Multiple System Atrophy and improve patient management.
How similar studies have performed: While the approach of using PET imaging for α-synuclein has been explored, this specific application in MSA is relatively novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age\> 35 years old, gender is not limited; * Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria; * all patients had been ruled out of polyQ disease by genetic testing; * Voluntarily participate in this study and sign the informed consent form. Exclusion Criteria: * pregnancy or breastfeeding; * contraindications to MRI examination or inability to cooperate in completing neuroimaging examination; * previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above); * History of alcohol or drug abuse
Where this trial is running
Hunan, Changsha
- Third Xiangya Hospital of Central South University — Hunan, Changsha, China (RECRUITING)
Study contacts
- Study coordinator: He RQ 何
- Email: hrq1234562001@163.COM
- Phone: 0086-18622148869
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple System Atrophy - Cerebellar Subtype, Multiple System Atrophy - Parkinsonian Subtype, Multiple System Atrophy, PETCT, α-synuclein